Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.

Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, Li Q. · 2022

Read Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. by Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, Li Q. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9052532.txt.

Introduction

Lu and co-authors review how gut microbes shape responses to cancer immunotherapy. Evidence from lab and clinic studies shows the gut community can raise or blunt the effect of checkpoint inhibitors. Microbes reprogram the tumor surroundings by engaging innate and adaptive immune cells. Their metabolites also travel beyond the gut and tune the body-wide response.

The review covers microbial signs that predict benefit or side effects. It then surveys strategies to harness the effect, from fecal transplants to probiotics and engineered microbes. The authors argue that these tools could sharpen precision care in cancer.

Catalog record

CREATORLu Y, Yuan X, Wang M, He Z, Li H, Wang J, Li Q.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE89 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9052532

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies By Yuting Lu, Xiangliang Yuan, Miao Wang, Zhihao He, Hongzhong Li, Ji Wang, Qin Li Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-022-01273-9 ABSTRACT Abstract The gut microbiota have long been recognized to play a key role in human health and disease. Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs). Deciphering the underlying mechanisms reveals that the gut microbiota reprogram the immunity of the tumor microenvironment (TME) by engaging innate and/or adaptive immune cells. Notably, one of the primary modes by which the gut microbiota modulate antitumor immunity is by means of metabolites, which are small molecules that could spread from their initial location of the gut and impact local and systemic antitumor immune response to promote ICI efficiency. Mechanistic exploration provides novel insights for developing rational microbiota-based therapeutic strategies by manipulating gut microbiota, such as fecal microbiota transplantation (FMT), probiotics, engineered microbiomes, and specific microbial metabolites, to augment the efficacy of ICI and advance the age utilization of microbiota precision medicine. Keywords: Cancer immunotherapy, Immune checkpoint inhibitors, Gut microbiota, Microbiota-derived metabolites, Therapeutic strategies BACKGROUND The microbiota in the gastrointestinal tract, which produces a myriad of small molecules and metabolites, play an essential role in multiple human physiological processes, including metabolism, inflammation, immunity, and neurology [1–5]. The function of the microbiota and its metabolites in modulating local and systemic immune responses has led to the emergence of research on the effects of the cancer-immune system and immune checkpoint inhibitor (ICI) therapeutic response [6–10]. The widespread variability in the gut microbiota across adult individuals is another reason to consider the gut microbiome as a potential source of phenotypic variability in cancer progression and ICI treatment outcomes [11]. Mounting evidence supports the role of the gut microbiota in the ICI response in preclinical and clinical studies [12–17]. ICI immunotherapy has improved traditional cancer therapeutic medicine and has enabled breakthroughs in the treatment of solid metastatic malignancies [18–21]. ICIs unleash immune brake responses and effectively inhibit tumor immune escape by targeting programmed cell death 1 (PD-1) and its ligand (PD-L1), lymphocyte-activating gene-3 (LAG3), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and other targets [18, 22, 23]. However, responses to ICI therapy are heterogeneous and not robust, with patient objective response rates (ORRs) of only 10–30% [24–27]. Manipulation of the gut microbiota provides novel insight for improving the antitumor immune response and expanding ICI efficacy. Nonetheless, the potential molecular mechanisms of the influence of the gut microbiome and its metabolites on ICI efficacy are still poorly understood in some cancer types. In this review, we have summarized studies of the influence of the gut microbiome on ICI efficacy and discussed the mechanisms of microbiota cross talk with innate and adaptive immune cells to ameliorate ICI responses. We will specifically highlight the mechanisms of microbiota-derived metabolites and molecule-mediated antitumor immune responses to ICI. Finally, we will review the therapeutic strategies and ongoing trials investigating manipulation of gut microbiota to improve ICI efficacy. GUT MICROBIOTA AND EFFICACY OF IMMUNOTHERAPY: FROM DISCOVERY TO APPLICATIONS Early studies have shown that gut microbiota could stimulate antitumor immune responses by modulating CD8+ T cells [28], T helper 1 (Th1) [29], and tumor-associated myeloid cells [30]. Indeed, the effects of cancer therapy were attenuated in antibiotic-treated or germ-free mouse models and were affected by special gut microbiota species. Importantly, landmark publications in 2015 in mouse models first linked the gut microbiota to ICI responses [16, 17]. Gut microbiota composition influenced anti-PD-L1 therapy responses, and the difference in responses was eliminated upon FMT or cohousing [16]. Oral administration of Bifidobacterium restored the antitumor efficacy of PD-L1 blockade by enhancing dendritic cell (DC) maturation and increasing CD8+ T cell priming and accumulation in the tumor microenvironment (TME) [16]. Another contemporary parallel study on anti-CTLA-4 therapy suggested that antibiotics dampen the antitumor effect of ICI, and supplementation with Bacteroides fragilis in germ-free or antibiotic-treated melanoma mice could augment anti-CTLA-4 therapeutic efficacy [17]. The microbiota-dependent antitumor effect is dependent on eliciting Th1-cell activation in the tumor draining lymph node and inducing maturation of intratumoral DCs [17]. Human studies published in Science side by side in 2018 complemented these mouse studies. The three studies all demonstrated that gut microbiota composition and diversity were predictive of response to ICI immunotherapy [31–33]. A similar finding was that fecal microbiota transplantation (FMT) from ICI responding patients to germ-free or antibiotic-treated mice could improve tumor control and ameliorate responses to ICI, whereas FMT from non-responders failed to do so [31–33]. In non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), patients with a higher diversity of bacteria were more sensitive to anti-PD-1 therapy [31]. Oral supplementation with Akkermansia muciniphila (A. muciniphila) after FMT from ICI non-responders restored anti-PD-1 therapy responses [31]. In melanoma patients, the diversity and composition of the gut microbiota were positively correlated with anti-PD-1 therapy responses [32]. Mostly, ICI responding patients with a higher abundance of Faecalibacterium and Ruminococcaceae in the gut displayed increased numbers of CD4+ T cells and CD8+ T cells in the periphery [32]. Another study involving patients with metastatic melanoma indicated that Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium were more abundant in the baseline feces of responders [33]. Prospective studies confirmed a significant association between gut microbiota and ICI outcomes in NSCLC, hepatocellular carcinoma (HCC), melanoma, and RCC patients from 2019 to 2020 [34–38]. At the same time, retrospective studies have implicated that antibiotics were associated with decreased survival and attenuated response to ICI in patients with advanced solid tumors [39–44], supporting a causal link between antibiotic-induced dysbiosis and poor therapeutic efficacy of ICI. Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15]. The timeline of gut microbiota and ICI efficacy is summarized in Fig. 1. [Figure: Timeline of gut microbiota and ICI efficacy: from discovery to application. From 2007 to 2013, mouse studies showed that the gut microbiota could stimulate antitumor immune responses. In 2015, two preclinical mouse studies first linked the gut microbiota to ICI responses. In 2018, mouse and human studies demonstrated that gut microbiota composition and diversity were predictive of the response to ICI immunotherapy. FMT from ICI responding patients to germ-free or antibiotic-treated mice could improve tumor control and ameliorate responses to ICI. From 2019 to 2020, prospective studies confirmed a significant association between gut microbiota and ICI outcomes in advanced solid tumors. Retrospective studies have implicated that antibiotics are associated with decreased survival and attenuated response to ICI. In 2021, two clinical trials found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients] In addition to modulating ICI immunotherapy, gut microbiota can influence adoptive T cell transfer (ACT) immunotherapy, CpG-oligodeoxynucleotide (CpG-ODN) immunotherapy, and cell-based immunotherapy. Antibiotic exposure decreased the efficacy of ACT therapy in mice [28, 45], while bacterial LPS supplementation restored the therapeutic effect via toll-like receptor (TLR) 4 signaling [28]. Another study demonstrated that the gut microbiota maintained ACT therapeutic efficacy by increasing the

Read the complete text